Alan Swaisland - Concepedia

Author

Alan Swaisland

AstraZeneca (United Kingdom)

Also Known As

A Swaisland, A. J. Swaisland, A. SWAISLAND, A. Swaisland, A.J. Swaisland, Alan J. Swaisland, Alan Swaisland

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)Institute of Cancer Research AstraZeneca (Brazil)AstraZeneca (United States)University of Ulster

About

Alan Swaisland is an author at AstraZeneca (United Kingdom) specializing in medicine, organic chemistry, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	191
2	Biochemistry	2	2	1.1K
3	Engineering	1	1	84
4	Health Sciences	1	1	110
5	Biomolecular Engineering	1	1	84

Alan Swaisland

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide Peter Sims, P.L. Grover, Alan Swaisland, Nature BiochemistryMetabolic ActivationMetabolismPolycyclic Aromatic HydrocarbonPrimary Metabolite	1974	1.1K
Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck J.S.W. Stewart, Ezra E.W. Cohen, Lisa Licitra, Journal of Clinical Oncology	2009	379
Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma David A. Reardon, Jennifer A. Quinn, James J. Vredenburgh, Clinical Cancer Research	2006	191
Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial R.A. Hannon, Glen Clack, Martin Rimmer, Journal of Bone and Mineral Research PharmacotherapyOsteoporosisOrthopaedic SurgeryBone DiseaseOncology	2009	110
Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors José Baselga, Andrés Cervantes, Erika Martinelli, Clinical Cancer Research	2010	108
Polycyclic hydrocarbon epoxides: The involvement of 8,9‐dihydro‐8,9‐dihydroxybenz (a) anthracene 10,11‐oxide in reactions with the DNA of benz (a) anthracene‐treated hamster embryo cells Alan Swaisland, Alan Hewer, K. Pal, FEBS Letters Hamster Embryo CellsEngineeringAnthracene 10,11‐OxideMolecular BiologyOrganic Chemistry	1974	84
Some properties of “K-region” epoxides of polycyclic aromatic hydrocarbons Alan Swaisland, Philip L. Grover, Peter Sims Biochemical Pharmacology Organic ChemistryPolycyclic Aromatic HydrocarbonsPolycyclic Aromatic HydrocarbonChemistry	1973	43
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study Ian Chau, David Cunningham, Tamas Hickish, Annals of Oncology Gastrointestinal OncologyMedicineColorectal CancerPathologyCancer Treatment	2007	40
Gefitinib–phenytoin interaction is not correlated with the<sup>14</sup>C‐erythromycin breath test in healthy male volunteers Stéphanie Chhun, Céline Verstuyft, N. Rizzo, British Journal of Clinical Pharmacology	2009	38
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib Jiří Horák, Jeff White, Adrian L. Harris, Cancer Chemotherapy and Pharmacology Hepatic DisordersHepatologyMedicineLiver PhysiologyHepatic Impairment	2011	28

Page 1